Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29433452 | 1.00 | TSHR (0.57) | TSHRLMNAALDH1A1HSP90AA1HTT | |
| SCHEMBL28728423 | 0.88 | TSHR (0.67) | TSHRLMNAALDH1A1HSP90AA1HTT | |
| SCHEMBL8713178 | 0.85 | TSHR (0.61) | TSHRLMNAALDH1A1HSP90AA1HTT | |
| SCHEMBL9124019 | 0.83 | ALDH1A1 (0.67) | TSHRLMNAALDH1A1HSP90AA1HTT | |
| SCHEMBL13622489 | 0.82 | ALDH1A1 (0.70) | TSHRLMNAALDH1A1HSP90AA1HTT | |
| SCHEMBL1459762 | 0.82 | ALDH1A1 (0.54) | TSHRLMNAALDH1A1HSP90AA1HTT | |
| SCHEMBL10729521 | 0.81 | TSHR (0.57) | TSHRLMNAALDH1A1HSP90AA1HTT | |
| SCHEMBL3874391 | 0.81 | ALDH1A1 (0.60) | TSHRLMNAALDH1A1HSP90AA1HTT | |
| SCHEMBL23252184 | 0.81 | ALDH1A1 (0.52) | TSHRLMNAALDH1A1HSP90AA1HTT | |
| SCHEMBL3881384 | 0.81 | ALDH1A1 (0.52) | TSHRLMNAALDH1A1HSP90AA1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | EPIVARIO, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-20220305010-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2022-09-29 | — | — | US | disclosed |
| EP-3983386-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | Metabomed Ltd (IL) | 2022-04-20 | — | — | EP | disclosed |
| CN-114008025-A | ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2020230136-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020230136-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2020-11-19 | — | — | WO | disclosed |
| US-20180065908-A1 | CHAIN MULTIYNE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | XIAMEN UNIVERSITY (CN) | 2018-03-08 | — | — | US | disclosed |
| US-9580395-B2 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580395-B2 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2017-02-28 | — | — | US | disclosed |
| US-20070219183-A1 | Dihydropyrazolo[1,5-A]pyrimidine and dihydroimidazo[1,5-A]pyrimidine derivatives and methods of use thereof | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| US-7241790-B2 | Compounds active in spinigosine 1-phosphate signaling | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070088002-A1 | Orally available sphingosine 1-phosphate receptor agonists and antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-04-19 | — | — | US | disclosed |
| EP-0817775-B1 | QUINAZOLINE DERIVATIVES | PFIZER (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-1110953-A1 | Quinazoline derivatives | PFIZER INC. (US) | 2001-06-27 | — | — | EP | disclosed |
| US-5747498-A | Alkynyl and azido-substituted 4-anilinoquinazolines | PFIZER INC. (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0817775-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| WO-1996030347-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| US-4219679-A | HIGH CONVERSION | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1980-08-26 | — | — | US | disclosed |
| US-4139561-A | RUTHENIUM HYDROGENATION CATALYST | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1979-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088002-A1 | Orally available sphingosine 1-phosphate receptor agonists and antagonists | S1PR3, S1PR1, S1PR5 | TSHR 232/4885LMNA 2126/4885ALDH1A1 4436/4885 |
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | TSHR 3842/4885LMNA 3876/4885ALDH1A1 238/4885 |
| US-20180065908-A1 | CHAIN MULTIYNE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | SQLE, COASY, MCCC2 | TSHR 3138/4885LMNA 1741/4885ALDH1A1 761/4885 |
| US-20220305010-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | TSHR 3842/4885LMNA 3876/4885ALDH1A1 238/4885 |
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, GLS2, ADSS2 | TSHR 3842/4885LMNA 3876/4885ALDH1A1 238/4885 |
| US-20070219183-A1 | Dihydropyrazolo[1,5-A]pyrimidine and dihydroimidazo[1,5-A]pyrimidine derivatives and methods of use thereof | DPYD, DUT, TYMP | TSHR 4614/4885LMNA 2561/4885ALDH1A1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.